Sun Pharma trades higher as its arm acquires Uractiv Portfolio
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Sun Pharmaceutical Industries is currently trading at Rs. 907.00, up by 6.45 points or 0.72% from its previous closing of Rs. 900.55 on the BSE.
The scrip opened at Rs. 899.00 and has touched a high and low of Rs. 912.25 and Rs. 898.50 respectively. So far 24014 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 652.75 on 18-Jun-2021.
Last one week high and low of the scrip stood at Rs. 931.00 and Rs. 893.95 respectively. The current market cap of the company is Rs. 216563.97 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 34.46% and 11.06% respectively.
Sun Pharmaceutical Industries’ subsidiary -- S.C. Terapia S.A., Romania has acquired the Uractiv portfolio from Fiterman Pharma in Romania. The Uractiv portfolio comprises food supplements including minerals, vitamins and adjuvants; cosmetics and medical devices used for maintaining urinary tract health.
Uractiv is the No. 1 brand in its category in Romania, trusted by consumers for more than 10 years. The portfolio including 12 SKUs has annualised revenues of approximately $8.7 million. The products cater to both adults and children. This acquisition is in line with company’s strategy to further expand its non-prescription product basket in Romania and neighbouring markets.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
.jpg)
